Published in Dalton Trans on July 11, 2011
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity. J Med Chem (2012) 0.82
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. Chem Commun (Camb) (2013) 0.81
Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity. Chem Biodivers (2012) 0.80
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromol Biosci (2016) 0.75
Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. Int J Mol Sci (2016) 0.75
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
Antitumour metal compounds: more than theme and variations. Dalton Trans (2007) 1.64
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev (2006) 1.55
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J Med Chem (2009) 1.51
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem (2009) 1.32
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem (2003) 1.25
Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat (2008) 1.24
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem (2007) 1.19
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem (2007) 1.08
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J Inorg Biochem (2010) 1.04
Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem (2011) 1.04
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. J Biol Inorg Chem (2010) 1.03
Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem (2007) 1.03
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J Inorg Biochem (2007) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans (2009) 1.00
Gallium in cancer treatment. Curr Top Med Chem (2004) 0.98
Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem (2011) 0.98
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem (2005) 0.97
Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. J Inorg Biochem (2002) 0.97
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem (2010) 0.96
Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. Eur J Med Chem (2011) 0.96
Carbohydrate-metal complexes and their potential as anticancer agents. Curr Med Chem (2008) 0.95
Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean. Sci Total Environ (2010) 0.93
Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. Inorg Chem (2007) 0.93
Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. Nucl Med Biol (2008) 0.93
The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. Inorg Chem (2007) 0.93
Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. J Inorg Biochem (2008) 0.92
Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. J Biol Inorg Chem (2012) 0.92
Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. Chem Commun (Camb) (2012) 0.92